The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Acute Lymphoblastic Leukemia in Adults⁎
⁎A separate evidence-based review and position statement are available for the role of SCT in pediatric ALL patients.34  by unknown
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3SBMT POSITION STATEMENT
he Role of Cytotoxic Therapy with Hematopoietic
tem Cell Transplantation in the Treatment of Acute
ymphoblastic Leukemia in Adults*
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4Among the primary objectives of the American
ociety for Blood and Marrow Transplantation are to:
Deﬁne commonly accepted medical practice
Develop standards of medical care for autologous
and allogeneic transplants
Provide recommendations and guidelines about
the role of transplantation as a therapeutic ap-
proach for reimbursement by third-party payers
o this end, in 1999 the Society began the develop-
ent of evidence-based reviews of the scientiﬁc and
A separate evidence-based review and position statement are
vailable for the role of SCT in pediatric ALL patients.3,4
Expert panel members and authors of the review are: Theresa
ahn, PhD, Roswell Park Cancer Institute, Buffalo, NY; Donna
all, MD, Texas Transplant Institute, San Antonio, TX; Bruce
amitta, MD, Midwest Children’s Center, Medical College of
isconsin and Children’s Hospital of Wisconsin, Milwaukee,
I; Stella Davies, MD, PhD, Cincinnati Children’s Hospital and
edical Center, Cincinnati, OH; Hildy Dillon, MPH, The
eukemia and Lymphoma Society, White Plains, NY; Paul
aynon, MD, Children’s Hospital of Los Angeles, Los Angeles,
A; Richard A. Larson, MD, University of Chicago, Chicago, IL;
usan Parsons, MD, Dana-Farber Cancer Institute/Harvard
edical School, and Tufts New England Medical Center/Tufts
niversity School of Medicine, Boston, MA; Jerome Seidenfeld,
lue Cross and Blue Shield Association Technology Evaluation
enter, Chicago, IL; Daniel Weisdorf, MD, University of
innesota, Minneapolis, MN; Philip L. McCarthy, Jr., MD,
oswell Park Cancer Institute, Buffalo, NY.
Reference: Hahn T, Wall D, Camitta B, et al. The role of
ytotoxic therapy with hematopoietic stem cell transplantation in
he therapy of acute lymphoblastic leukemia in adults: an
vidence-based review. Biol Blood Marrow Transplant. 2006;12:1-
0.
Reference: Hahn T, Wall D, Camitta B, et al. The role of
ytotoxic therapy with hematopoietic stem cell transplantation in
he therapy of acute lymphoblastic leukemia in children: an
vidence-based review. Biol Blood Marrow Transplant. 2005;11:
23-861.
Reference: ASBMT Position Statement: The role of cytotoxic
herapy with hematopoietic stem cell transplantation in the
reatment of acute lymphoblastic leukemia in children. Biol Blood
arrow Transplant. 2006;12:370-371.
68edical literature to document when blood and mar-
ow transplantation is indicated in the treatment of
elected diseases.
oals
The goals of the evidence-based reviews are to:
Determine which disease will be the subject of
each review, establish the focus for each review,
and develop a list of questions to be addressed
Assemble and critically evaluate all the evidence
regarding the role of cytotoxic therapy with he-
matopoietic stem cell transplantation related to
the disease and the questions to be addressed in
each review
Make treatment recommendations based on the
available evidence
Identify discrepancies in study design or method-
ology among published studies that may impact
the quality of the evidence
Identify needed areas of additional study
uidelines
The following guidelines are offered for the role
f stem cell transplantation (SCT) as therapy for acute
ymphoblastic leukemia (ALL) in adults and are based
n consensus reached by an expert panel1 following an
vidence-based review of the literature2:
. In ﬁrst complete remission (CR1), SCT yields out-
comes similar to chemotherapy and is not recom-
mended as ﬁrst-choice therapy. For high-risk pa-
tients, there are no direct comparisons but some
data suggest an advantage for SCT.
. In second complete remission (CR2), SCT is rec-
ommended over chemotherapy as a sizeable frac-
tion of patients achieve extended leukemia-free
survival compared to chemotherapy alone.
. Autologous purged SCT and autologous unpurged
SCT produce leukemia-free survival comparable to
chemotherapy.
. Although there are no direct comparisons, there ap-
pears to be a survival advantage for related allogeneic
SCT compared to chemotherapy in Ph adult ALL
patients in CR1 or subsequent remissions.
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ASBMT Position Statement
B. Unrelated allogeneic SCT produces extended leu-
kemia-free survival in some patients. Although
there are no direct comparisons, there is a possible
beneﬁt of unrelated allogeneic SCT over chemo-
therapy in Ph adult ALL patients. Higher treat-
ment-related mortality, however, may compromise
the potential anti-tumor advantage of unrelated
allogeneic SCT.
. There are not enough data to recommend one
conditioning regimen over another, although there
appears to be an advantage to TBI-containing
compared to non–TBI-containing regimens.
. There are not enough data evaluating nonmyelo-
ablative conditioning regimens to determine the
effect on treatment-related mortality and leuke-
mia-free survival. No recommendation can be
made.
. A preponderance of evidence supports a recom-
mendation of allogeneic over autologous SCT.
There is insufﬁcient evidence, however, to deter-
mine if this effect is more apparent in speciﬁc risk
subgroups, including Ph adult ALL. T
B & M T. The following are recommended as the most im-
portant areas of needed research:
● Monitoring of minimal residual disease and
disease control before SCT
● Comparison of non-family (unrelated bone mar-
row or cord blood) donor vs. autologous SCT
● Deﬁnition of high risk groups, beyond Ph
status, in CR1 with formal testing of SCT vs.
other treatments
● Analysis of the graft-versus-leukemia effect in
reduced intensity vs. myeloablative condition-
ing regimens
● Outcomes data for SCT in older (50 years)
patients with ALL
● Evaluation of the impact of imatinib and other
tyrosine kinase inhibitors on SCT for Ph
ALL
—Adopted by the ASBMT Executive Committee
on September 29, 2005
2006 American Society for Blood and Marrow
ransplantation
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